These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30305612)

  • 1. BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways.
    Chen XX; Yin Y; Cheng JW; Huang A; Hu B; Zhang X; Sun YF; Wang J; Wang YP; Ji Y; Qiu SJ; Fan J; Zhou J; Yang XR
    Cell Death Dis; 2018 Oct; 9(10):1036. PubMed ID: 30305612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss.
    Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M
    Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
    Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
    Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
    Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
    J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
    Chen J; Li Z; Chen J; Du Y; Song W; Xuan Z; Zhao L; Song G; Song P; Zheng S
    Clin Transl Oncol; 2020 Mar; 22(3):392-400. PubMed ID: 31264147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of downregulation of WWOX with poor prognosis in patients with intrahepatic cholangiocarcinoma after curative resection.
    Huang C; Tian Y; Peng R; Zhang C; Wang D; Han S; Jiao C; Wang X; Zhang H; Wang Y; Li X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):421-33. PubMed ID: 25168293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium-sensing receptor promotes tumor proliferation and migration in human intrahepatic cholangiocarcinoma by targeting ERK signaling pathway.
    Fang Y; Liu L; Liu S; Hu L; Cai W; Wan X; Liu D; He Y; Zhu Z
    Eur J Pharmacol; 2020 Apr; 872():172915. PubMed ID: 31926993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.
    Andrici J; Goeppert B; Sioson L; Clarkson A; Renner M; Stenzinger A; Tayao M; Watson N; Farzin M; Toon CW; Smith RC; Mittal A; Samra JS; Hugh TJ; Chou A; Lawlor RT; Weichert W; Schirmacher P; Sperandio N; Ruzzenente A; Scarpa A; Gill AJ
    Medicine (Baltimore); 2016 Jan; 95(2):e2491. PubMed ID: 26765459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
    Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
    Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer.
    Sakamoto K; Imai K; Higashi T; Taki K; Nakagawa S; Okabe H; Nitta H; Hayashi H; Chikamoto A; Ishiko T; Beppu T; Baba H
    Cancer Sci; 2015 Sep; 106(9):1153-62. PubMed ID: 26132727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
    Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
    Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
    Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
    BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
    Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
    Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma.
    Xie N; Cai JB; Zhang L; Zhang PF; Shen YH; Yang X; Lu JC; Gao DM; Kang Q; Liu LX; Zhang C; Huang XY; Zou H; Zhang XY; Song ZJ; Sun HX; Fu BM; Ke AW; Shi GM
    Cell Death Dis; 2017 Dec; 8(12):3205. PubMed ID: 29235470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
    Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
    HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Homer1 as a potential prognostic marker for intrahepatic cholangiocarcinoma.
    Wu SY; Yu MX; Li XG; Xu SF; Shen J; Sun Z; Zhou X; Chen XZ; Tu JC
    Asian Pac J Cancer Prev; 2014; 15(7):3299-304. PubMed ID: 24815486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma.
    Huang Y; Kong Y; Zhang L; He T; Zhou X; Yan Y; Zhang L; Zhou D; Lu S; Zhou J; Zhou L; Xie H; Zheng S; Wang W
    Biomed Res Int; 2018; 2018():2352139. PubMed ID: 29511671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LRRK2 Is Associated with Recurrence-Free Survival in Intrahepatic Cholangiocarcinoma and Downregulation of LRRK2 Suppresses Tumor Progress In Vitro.
    Gu S; Chen J; Zhou Q; Yan M; He J; Han X; Qiu Y
    Dig Dis Sci; 2020 Feb; 65(2):500-508. PubMed ID: 31489563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-21 regulates the invasion and metastasis in cholangiocarcinoma and may be a potential biomarker for cancer prognosis.
    Huang Q; Liu L; Liu CH; You H; Shao F; Xie F; Lin XS; Hu SY; Zhang CH
    Asian Pac J Cancer Prev; 2013; 14(2):829-34. PubMed ID: 23621247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos.
    Brandi G; Deserti M; Palloni A; Turchetti D; Zuntini R; Pedica F; Frega G; De Lorenzo S; Abbati F; Rizzo A; Di Marco M; Massari F; Tavolari S
    Cancer Genet; 2020 Oct; 248-249():57-62. PubMed ID: 33093002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.